ANAEMIA IS COMMON in patients with myelomatosis. Nearly half the patients entering the third MRC myelomatosis trial had an initial haemoglobin concentration of 10 g/dl or less (MRC Working Party, 1980a) . The haemoglobin concentration on presentation was strongly correlated with prognosis in patients with good renal function (ibid.) though in patients with poor renal function it appeared to give little prognostic information. The pathogenesis of anaemia in patients with myelomatosis and the reasons for its prognostic significance are unknown. The purpose of the present study is to characterize the anaemia found in newly diagnosed, untreated patients, using standard haematological and ferrokinetic techniques. These results have been related to measurements of erythropoietin, the erythropoietin sensitivity of marrow cultures and haem synthesis in erythroblasts.
PATIENTS AND METHODS
Patients.-Twenty-four newly diagnosed, untreated patients with myelomatosis gave their fully informed consent to the investigations carried out in this study. There were 12 male and 12 female patients, aged 43-89 years (mean 65). The diagnosis of myelomatosis was based on at least 2 of the following 3 criteria: (1) marrow smears showing the presence of abnormal plasmacell infiltration, (2) radiological evidence of definite osteolytic lesions, (3) paraprotein or Bence Jones protein in the serum or urine. Patients presenting with renal failure were adequately hydrated before any investigations were carried out.
The patients were clasisfied by their haemoglobin concentration, serum calcium, serum and urine paraprotein and light-chain concentrations, and radiological lesions at presentation into 3 clinical stages, according to the method of Durie & Salmon (1975) . There were 10 patients with IgG myeloma, 7 with IgA myeloma, I with IgM myeloma, 4 with K light-chain myeloma and 2 with A lightchain myeloma. Thirteen patients had Bence Jones proteinuria. Haematological and ferrokinetic data were also available from 11 male and 9 female normal healthy adult volunteers aged 27-64 years (mean 40). Marrow cultures were carried out on samples from 7 male and 7 female normal adults, aged 20-64 years (mean 51).
Methods. Counter model S. Serum iron concentration and total iron-binding capacity were measured by a modification of the method of Young & Hicks (1965) . Serum ferritin concentration was measured by the immunoradiometric assay described by Jones & Worwood (1975) . The method of Tennant (1977) was used to measure the serum and red-cell folate concentrations. The serum paraprotein type was determined by immunoelectrophoresis. The concentration of normal immunoglobulins was measured by radial agar immunodiffusion (Fahey & McKelvey, 1965) using commercially available standards. Serum erythropoietin concentration was assayed using foetal mouse liver cell cultures by the technique of Napier & Evans (1980) . Ferrokinetic measurements were made of erythroid and non-erythroid iron turnover and mean red-cell lifespan, together with plasma volume and total red-cell volume by the methods described by Ricketts et al. (1975) and Cavill et al. (1977) . Total marrow erythroblast population and the mean in vivo erythroblast iron uptake were estimated from measurements of the radioactivity in marrow cells aspirated 20-24 h after i.v. injection of [59Fe] transferrin (Cavill & Fisher, in preparation) . The total radioactivity in the marrow at this time wvas derived by analysis of the plasma iron clearance and red-cell utilization curves. The total number of erythroblasts in the marrow was calculated from this value and the measured activity of the known number of nucleated red cells in the marrow sample. The total marrow plasma-cell population was calculated from the total marrow erythroblast count, assuming that the plasma cell/ erythroblast ratio in the marrow aspirate was representative of the total marrow.
Erythroblast iron metabolism was also studied in vitro in aspirated marrow samples.
Washed marrow cells were incubated for 1 h in Hepes buffered MEM (pH 7.4) containing 2 mg/ml transferrin. 38% saturated with [59Fe] ferric iron. At the end of this time total iron uptake in erythroblasts was measured. The washed cells were then sonicated and 59Fe was measured in the cell stroma after centrifugation at 45,000 g for 30 min. 59Fe in haem was measured after butanone extraction of the supernatant cytosol, and 59Fe incorporation into ferritin was measuired after precipitation by rabbit antihuman-spleen ferritin following the addition of carrier ferritin. The remaining cytosol 59Fe in unidentified soluble complexes was also measured.
The erythropoietin (Epo) response of marrow cells was measured in liquid culture by a modification of the method described by Krantz et al. (1963 Krantz et al. ( , 1973 Teale (1959) . The incorporation of 59Fe into haem was then counted in an LKB 80,000 automatic gamma counter. None of the parameters measured showed a Normal distribution. Correlations wNere assessed using Spearman's rank correlation coefficient and difference between groups by the MannWhitmey U test (Siegel, 1956 
Renal function
Six patients had a blood-urea concentration of > 10 mm and 5 had a serum creatinine of > 200 jM. There was a significant negative correlation between haemoglobin concentration and serum creatinine (rs = -052, P < 0.05) but no correlation between the concentrations of haemoglobin and blood urea (rs = -0*31, P<0-1). Neither haemoglobin concentration, marrow iron turnover, IgG (10)* IgA (7) IgM (1) Serum immunoglobulins (g/l)
IgG (14) IgA (18) IgM (23) * No. of patients in brackets.
haem synthesis nor the in vitro response of the marrow to Epo were significantly different between patients with blood urea concentrations above and below 10 mM.
Immunoglobulins
The serum paraprotein levels of the patients are summarized in Table 1 . Thirteen patients had immunoparesis and their immunoglobulins were below the normal laboratory reference value shown in Table I . The serum paraprotein level was significantly correlated with the percentage of plasma cells in the marrow (rs = 0*70, P < 001) with the total marrow plasma cells (rs=0.76, P<0-01), total blood volume (rs = 0-63, P < 0.05) and with serum folate concentration (rs= -0 73, P<0-001). In the patients with light-chain myeloma, urinary concentration of light chains varied between 0 4 and 12*1 g/l (mean 5.0 g/l).
Haematological status
The haematological and biochemical statuses of the patients are summarized in Table I . Nine of the patients had a haemoglobin concentration of < 10 g/dl. There was a significant negative correlation between haemoglobin concentration and serum paraprotein (rs = -056, P < 0.05), total marrow plasma cells (r,= -0-62, P<0 05) and total blood volume (rs= -0-71, P<0-01). Haemoglobin concentration was significantly correlated with the percentage of plasma cells in the marrow (rs= -0'43, P < 0.05).
Stainable iron was present in the marrow of all the patients, but no sideroblasts or megaloblasts were seen. Four patients had both low serum iron and total iron binding capacity, but a low transferrin saturation was found only in 3 patients. No patient had a serum ferritin < 15 jug/l, the level conventionally denoting iron deficiency. One patient had a low serum folate (1-9 ,ug/l) and red-cell folate of 60 [kg/l.
Serum erythropoietin
The serum Epo concentrations of the uraemic patients were all within the normal range of 3-30 mu/ml (Fig. 1) In vitro marrow responses to erythropoietin The effect of erythropoietin on haem synthesis after 4 day culture of marrow samples is shown in Fig. 3 In normal subjects (Cavill & Ricketts, 1980) there is a significant negative correlation between marrow iron turnover and red-cell lifespan, and this is true for the present normal group (rs = -0 73, P<0.001) and for patients with myelomatosis (rs=-0-88, P<0.001) but, as can be seen from Fig. 2 , the marrow iron turnover in myeloma patients is lower than normal, for the corresponding red- (Innes & Newall, 1961) and 62°, of a series seen in the Mayo Clinic up to 1971 (Kyle, 1975) . 237 out of 485 patients entering the third MIRC myelomatosis trial had an initial haemoglobin concentration of 1]0 g/dl or less (MRC Working Party, 1980b) . The anaemia has usually been described as normochromic or normocytic (Innes & Newall, 1961; Kyle, 1975) and may be the result of haemodilution due to an expanded plasma volume (Bjorneboe & Jensen, 1969 : Alexanian, 1977 though this is by no means universally agreed (Cline & Berlin, 1962; Hansen & Drivsholm, 1 978) . It has been suggested that the haematological changes in myelomatosis result from displacement of normnal marrow by an abnormal growth of plasma cells (Innes & Newall, 1961; Kyle, 1975) . In addition, megaloblastic erythropoiesis due to both folate and B12 deficiency has been found in a high proportion of cases (Hoffbrand et al., 1967) andl about a (uarter of patients have been estimated1 to be iron deficient (Hansen, 1978 : Birgens et al., 1979 Dacie & Mollin, 1966) and this feature may precede the occurrence of myelomatosis in some cases (Catovsky et al., 1971) . In some patients on long-term chemotherapy for myelomatosis, sideroblastic anaemia may precede the onset of actute leukaemia (Khaleeli et al., 1973 (Fig. 1) . These findings differ from those of Hansen et al. (1977) , who found that most of their patients had no detectable circulating Epo. This may have been due to the lowr sensitivity of their Epo assay, based on post-hypoxic protein-starved mice. The mean blood volume of otur myeloma patientis was 68 6 ml/kg, compared to 63 0 ml/kg in normal subjects, and although this difference is statistically significant, its physiological significance may not be great. However, the negative correlation between haemoglobin concentration and blood v-olume in the patient indicates that haemodilution is probably a factior in the pathogenesis of their anaemia. The correlation between paraprotein concentration and blood volume suggests that plasma volume expansion is directly related to the protein abnormality. There is Ino relationship between blood volume and paraprotein type in our patients. The present findings are in agreement with those of Alexanian (1977) and Bjorneboe & Jensen (1969) However, Cline & Berlin (1962) and Hansen & Drivsholm (1978) Our myeloma patients showed a decrease(l rate of marrow iron turnover, while red-cell lifespan and ineffective erythropoiesis remained normal. This points to a significant impairment of the erythroid proliferative response to anaemia. The erythroblasts produced appear to behave normally. Although erythroblast iron uptake was increased in a few cases, haem synthesis was normal an(d no abnormal sideroblasts were seen. The factors controlling erythroid iron uptake are not understood. The only previous observations of increased uptake have been in patients with iron deficiency or secondary sideroblastic change (unpublishedl observations) neither of which are present, in the cases studied here.
The Epo response of the late erythroid precursors in marrow cultures was simila,r in normal and myeloma groups as a whole, but the patients showed far more variability than the control subjects, and in many cases the total iron incorporated into haem after Epo stimulation was 893 subnormal. It is difficult to judge from the present data whether decreased response to Epo may sometimes be important The reduction in total erythropoiesis measured by ferrokinetics, together with normal erythoblast iron uptake, suggests a reduced input from a precursor compartment, presumably due to a failure of maturation, though whether this is manifested at BFU-E or CFU-E level is not obvious. Except in patients with renal failure, the level of circulating Epo does not appear to be a limiting factor. In individual cases a superimposed folate deficiency may be important, and there appears to be a haemodilution factor related to the concentration of circulating paraprotein. The impression of a contracted erythroid marrow compartment in myeloma patients is similar to that found in patients with Hodgkin's disease (Al Ismail et al., 1979) but in neither case is there any direct indication of the precise mechanism.
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